Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 3/20 | 0.38 |
| ▸ | LIPE | Q05469 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.35 |
| ▸ | STS | P08842 | 2/20 | 0.34 |
| ▸ | TACR1 | P25103 | 2/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30392252 | 1.00 | RORC (0.38) | RORCLIPETSHRUSP30GPR119 | |
| SCHEMBL26105566 | 1.00 | RORC (0.38) | RORCLIPETSHRUSP30GPR119 | |
| SCHEMBL26105464 | 0.82 | USP2 (0.43) | RORCGPR119STSHDAC4 | |
| SCHEMBL26104643 | 0.82 | USP2 (0.43) | RORCGPR119STSHDAC4 | |
| SCHEMBL26105375 | 0.82 | RORC (0.43) | RORCUSP30GPR119STSTACR1 | |
| SCHEMBL31223970 | 0.81 | PDE4B (0.37) | RORCTSHRUSP30GPR119STS | |
| SCHEMBL31165531 | 0.80 | RORC (0.41) | RORCUSP30GPR119STSTACR1 | |
| SCHEMBL26102514 | 0.77 | HSP90AA1 (0.33) | RORCTSHRGPR119TACR1HSP90AA1 | |
| SCHEMBL31165545 | 0.75 | STS (0.47) | GPR119STS | |
| SCHEMBL31224487 | 0.75 | USP30 (0.37) | RORCTSHRUSP30GPR119STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4436667-B1 | PIPERAZINYLSULFONYLARYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN LA ROCHE (CH) | 2026-01-21 | — | — | EP | disclosed |
| US-20250011300-A1 | PIPERAZINYLSULFONYLARYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN-LA ROCHE INC. (US) | 2025-01-09 | — | — | US | disclosed |
| CN-118201916-A | Piperazinylsulfonylaryl compounds for the treatment of bacterial infections | 豪夫迈·罗氏有限公司 | 2024-06-14 | — | — | CN | disclosed |
| WO-2023072794-A1 | PIPERAZINYLSULFONYLARYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011300-A1 | PIPERAZINYLSULFONYLARYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | ABL1, Q6ZSR9, NQO2 | RORC 1773/4885LIPE 4415/4885TSHR 2563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.